| abstract |
The present invention is related to a compound or the pharmacologically acceptable salt having excellent antagonism to neurokinin NK1, neurokinin NK2, and muscarine M3 receptors and useful to be the therapeutic agent of bronchial asthma, chronic obstructive pulmonary disease and the like. It provides a compound represented by the general formula (I) or the pharmacologically acceptable salt [wherein, R1 is a hydrogen atom, C1-C6alkyl etc.; R2 is a hydrogen atom, C1-C6 alkyl etc.; R3 is a phenyl optionally substituted by one to five substituents independently selected from the substituent group A etc.; R4 is a phenyl optionally substituted by one to five substituents independently selected from the substituent group A etc.; L1 is C1-C10alkylene etc.; L2 is carbonyl, the formula represented by -N(R5)-C(=O)-, formula represented by -C(=O)-N(R5)-, and the like; R5 is a hydrogen atom, C1-C6alkyl etc.; E is phenylene optionally substituted by one to four substituents independently selected from the substituent group A etc.; m is an integer of 1 to 4; n is an integer of 0 to 4; p is an integer of 0 to 2; q is an integer of 1 to 10; r is 1 or 2; s is 0 or 1; substituent group A are halogen atoms, C1-C6alkyl, C1-C6haloalkyl etc.]. |